Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06253130
Title A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eikon Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Sarah Cannon Research Institute Health One RECRUITING Denver Colorado 80218 United States Details
Advent Health Research Institute RECRUITING Celebration Florida 34747 United States Details
Sarah Cannon Research Institue Oncology RECRUITING Nashville Tennessee 37203 United States Details
START - South Texas Accelerated Research Therapeutics RECRUITING San Antonio Texas 78229 United States Details
START Mountain Region RECRUITING West Valley City Utah 84119 United States Details
Scientia Clinical Research Ltd NOT_YET_RECRUITING Randwick New South Wales 2031 Australia Details
Mater Cancer Care Centre, Mater Misericordiae Limited NOT_YET_RECRUITING South Brisbane Queensland 4101 Australia Details
Gold Coast Private Hospital NOT_YET_RECRUITING Southport Queensland 4125 Australia Details
Macquarie University NOT_YET_RECRUITING Sydney Queensland 2109 Australia Details
Princess Alexandra Hospital NOT_YET_RECRUITING Woolloongabba Queensland 4102 Australia Details
Peninsula and south eastern haematology and oncology group NOT_YET_RECRUITING Frankston Victoria 3199 Australia Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field